Novimmune
FDA approves first ever therapy for ultra rare primary haemophagocytic lymphohistiocytosis
November 21, 2018Research and Development, Sales and Marketing FDA, Novimmune, pharma, sobi
The partnership of Sobi and Novimmune has revealed that their interferon gamma (IFNγ) blocking antibody Gamifant (emapalumab-lzsg) has received approval …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
